Comparison among Clark's, Breslow's, and TNM classifications for cutaneous head and neck malignant melanoma

Journal of Craniofacial Surgery

Volumn 18, Issue 6, 2007, Pages 1353-1358

  Morselli, Paolo ^a   Masciotra, Loredana ^a   Pinto, Valentina ^a   Zollino, Ilaria ^b   Brunelli, Giorgio ^b   Carinci, Francesco ^b  

^a UNIVERSITY OF BOLOGNA   (Italy)

^b UNIVERSITY OF FERRARA   (Italy)

Author keywords

Classification; Cox analysis; Head and neck; Melanoma; Skin

Indexed keywords

ADULT; AGED; ARTICLE; CANCER STAGING; CANCER SURGERY; CANCER SURVIVAL; CLINICAL EFFECTIVENESS; CONTROLLED STUDY; FEMALE; FOLLOW UP; HEAD AND NECK CANCER; HISTOPATHOLOGY; HUMAN; INTERMETHOD COMPARISON; MAJOR CLINICAL STUDY; MALE; MELANOMA; METASTASIS; NECK DISSECTION; NECK TUMOR; OUTCOME ASSESSMENT; PRIORITY JOURNAL; PROGNOSIS; RETROSPECTIVE STUDY; STATISTICAL SIGNIFICANCE; SURVIVAL TIME;

ADULT; AGED; AGED, 80 AND OVER; ANALYSIS OF VARIANCE; FEMALE; HEAD AND NECK NEOPLASMS; HUMANS; MALE; MELANOMA; MIDDLE AGED; NECK DISSECTION; NEOPLASM RECURRENCE, LOCAL; NEOPLASM STAGING; PROGNOSIS; PROPORTIONAL HAZARDS MODELS; RETROSPECTIVE STUDIES; SKIN NEOPLASMS;

EID: 36048941378     PISSN: 10492275     EISSN: None     Source Type: Journal    
DOI: 10.1097/scs.0b013e3180534453     Document Type: Article

References (42)

1. Quinn MJ, Crotty KA, Thompson JF, et al. Desmoplastic and desmoplastic neurotropic melanoma: experience with 280 patients. Cancer 1998;83:1128-1135
2. Elder DE, Van Belle P, Elenitsas R, et al. Neoplastic progression and prognosis in melanoma. Semin Cutan Med Surg 1996;15:336-348
3. Guerry DT, Synnestvedt M, Elder DE, et al. Lessons from tumor progression: the invasive radial growth phase of melanoma is common, incapable of metastasis, and indolent. J Invest Dermatol 1993;100:342S-345S
4. Clark WH Jr, Elder DE, Guerry DT, et al. Model predicting survival in stage I melanoma based on tumor progression. J Natl Cancer Inst 1989;81:1893-1904
5. Normal J, Cruse CW, Wells KE, et al. Metastatic melanoma with an unknown primary. Ann Plast Surg 1992;28:81-84
6. Elwood JM. Melanoma and sun exposure. Semin Oncol 1996;23:650-666
7. Landis SH, Murray T, Bolden S, et al. Cancer statistics, 1998. CA Cancer J Clin 1998;48:6-29
8. Whiteman DC, Stickley M, Watt P, et al. Anatomic site, sun exposure, and risk of cutaneous melanoma. J Clin Oncol 2006;24:3172-3177
9. White E, Kirkpatrick CS, Lee JA. Case-control study of malignant melanoma in Washington State. Part I. Constitutional factors and sun exposure. Am J Epidemiol 1994;139:857-868
10. Austin JR, Byers RM, Brown WD, et al. Influence of biopsy on the prognosis of cutaneous melanoma of the head and neck. Head Neck 1996;18:107-117
11. Breslow A. Thickness, cross-sectional areas and depth of invasion in the prognosis of cutaneous melanoma. Ann Surg 1970;172:902-908
12. Heaton KM, Sussman JJ, Gershenwald JE, et al. Surgical margins and prognostic factors in patients with thick (>4 mm) primary melanoma. Ann Surg Oncol 1998;5:322-328
13. Clark WH Jr, From L, Bernardino EA, et al. The histogenesis and biologic behavior of primary human malignant melanomas of the skin. Cancer Res 1969;29:705-727
14. Sobin LH, Wittekind Ch, Amin M, et al. TNM Classification of Malignant Tumors. New York: Wiley, 2002
15. Daryanani D, Plukker JT, de Jong MA, et al. Increased incidence of brain metastases in cutaneous head and neck melanoma. Melanoma Res 2005;15:119-124
16. Kienstra MA, Padhya TA. Head and neck melanoma. Cancer Control 2005;12:217-218
17. Cascinelli N. Margin of resection in the management of primary melanoma. Semin Surg Oncol 1998;14:272-275
18. Balch CM, Urist MM, Karakousis CP, et al. Efficacy of 2-cm surgical margins for intermediate-thickness melanomas (1 to 4 mm): results of a multi-institutional randomized surgical trial. Ann Surg 1993;218:262-267
19. Harris TJ, Hinckley DM. Melanoma of the head and neck in Qeensland. Head Neck Surg 1983;5:197-203
20. Sekido M, Yamamoto Y, Tsutsumida A, et al. Reconstructive considerations after resection of malignant melanoma in the head and neck. Scand J Plast Reconstr Surg Hand Surg 2005;39:222-226
21. Morton DL, Wen DR, Wong JH, et al. Technical details of intraoperative lymphatic mapping for early stage melanoma. Arch Surg 1992;127:392-399
22. Gogel BM, Kuhn JA, Ferry KM, et al. Sentinel lymph node biopsy for melanoma. Am J Surg 1998;176:544-547
23. Doting EH, de Vries M, Plukker JT, et al. Does sentinel lymph node biopsy in cutaneous head and neck melanoma alter disease outcome? J Surg Oncol 2006;93:564-570
24. Bonnen MD, Ballo MT, Myers JN, et al. Elective radiotherapy provides regional control for patients with cutaneous melanoma of the head and neck. Cancer 2004;100:383-389
25. Kirkwood JM, Strawderman MH, Ernstoff MS, et al. Interferon alfa-2b adjuvant therapy of high-risk resected cutaneous melanoma: the Eastern Cooperative Oncology Group Trial EST 1684. J Clin Oncol 1996;14:7-17
26. Legha SS, Ring S, Bedikian A, et al. Treatment of metastatic melanoma with combined chemotherapy containing cisplatin, vinblastine and dacarbazine (CVD) and biotherapy using interleukin-2 and interferon-alpha. Ann Oncol 1996;7:827-835
27. Atkins MB, Gollob JA, Sosman JA, et al. A phase II pilot trial of concurrent biochemotherapy with cisplatin, vinblastine, temozolomide, interleukin 2, and IFN-alpha 2B in patients with metastatic melanoma. Clin Cancer Res 2002;8:3075-3081
28. Falkson CI, Ibrahim J, Kirkwood JM, et al. Phase III trial of dacarbazine versus dacarbazine with interferon alpha-2b versus dacarbazine with tamoxifen versus dacarbazine with interferon alpha-2b and tamoxifen in patients with metastatic malignant melanoma: an Eastern Cooperative Oncology Group study. J Clin Oncol 1998;16:1743-1751
29. Keilholz U, Goey SH, Punt CJ, et al. Interferon alfa-2a and interleukin-2 with or without cisplatin in metastatic melanoma: a randomized trial of the European Organization for Research and Treatment of Cancer Melanoma Cooperative Group. J Clin Oncol 1997;15:2579-2588
30. Rosenberg SA, Yang JC, Schwartzentruber DJ, et al. Prospective randomized trial of the treatment of patients with metastatic melanoma using chemotherapy with cisplatin, dacarbazine, and tamoxifen alone or in combination with interleukin-2 and interferon alfa-2b. J Clin Oncol 1999;17:875-968
31. Fernandez N, Duffour MT, Perricaudet M, et al. Active specific T-cell-based immunotherapy for cancer: nucleic acids, peptides, whole native proteins, recombinant viruses, with dendritic cell adjuvants or whole tumor cell-based vaccines: principles and future prospects. Cytokines Cell Mol Ther 1998;4:53-65
32. Maeurer MJ, Storkus WJ, Kirkwood JM, et al. New treatment options for patients with melanoma: review of melanoma-derived T-cell epitope-based peptide vaccines. Melanoma Res 1996;6:11-24
33. Slingluff CL Jr. Tumor antigens and tumor vaccines: peptides as immunogens. Semin Surg Oncol 1996;12:446-453
34. Escobar A, Lopez M, Serrano A. Dendritic cell immunizations alone or combined with low doses of interleukin-2 induce specific immune responses in melanoma patients. Clin Exp Immunol 2005;142:555-556
35. Gillgren P, Mansson-Brahme E, Frisell J, et al. A prospective population-based study of cutaneous malignant melanoma of the head and neck. Laryngoscope 2000;110:1498-1504
36. Ringborg U, Afzelius LE, Lagerlof B, et al. Analysis of treatment results and prognostic factors in 581 patients: a report from the Swedish Melanoma Study Group. Cancer 1993;71:751-758
37. Hoersch B, Leiter U, Garbe C. Is head and neck melanoma a distinct entity? A clinical registry-based comparative study in 5702 patients with melanoma. Br J Dermatol 2006;155:771-777
38. Bogle M, Kelly P, Shenaq J, et al. The role of soft tissue reconstruction after melanoma resection in the head and neck. Head Neck 2001;23:8-15
39. Frokiaer E, Kiil J, Sogaard H. The use of skin flaps in the treatment of malignant melanomas in the head and neck region. Scand J Plast Reconstr Surg 1982;16:157-161
40. Cho E, Rosner BA, Colditz GA. Risk factors for melanoma by body site. Cancer Epidemiol Biomarkers Prev 2005;14:1241-1244
41. Dawson-Saunders B, Trapp RG. Basic and Clinical Biostatistics. Norwalk: Appleton & Lange, 1994
42. Cox DR, Oakes D. Analysis of Survival Data. New York: Chapman & Hall, 1984